The FDA has authorized urcosimod 0.05% for single-patient expanded access, or compassionate use, in a patient with neuropathic corneal pain, according to a press release from Okyo.

Scientific American is the essential guide to the most awe-inspiring advances in science and technology, explaining how they change our understanding of the world and shape our lives.